In:
Hepatology Research, Wiley, Vol. 45, No. 7 ( 2015-07), p. 745-754
Abstract:
This study assessed the efficacy and safety of telaprevir in combination with peginterferon‐α‐2b ( PEG IFN ) and ribavirin ( RBV ), for Japanese difficult‐to‐treat patients with hepatitis C virus ( HCV ) genotype 2 who had not achieved sustained virological response ( SVR ) during prior treatment. Methods In total, 108 relapsed (median age, 59.0 years) and 10 non‐responding (median age, 59.0 years) patients with genotype 2 HCV participated. Patients received telaprevir (750 mg, every 8 h) for 12 weeks and PEG IFN / RBV for 24 weeks. Results The SVR rates for relapsers and non‐responders were 88.0% (95/108) and 50.0% (5/10), respectively. The SVR rates did not differ significantly between patients with rs8099917 TT and non‐ TT . The SVR rates for relapsers and non‐responders with extended rapid viral response ( eRVR ) were 97.6% (82/84) and 100% (5/5), respectively. On the other hand, the SVR rates for relapsers and non‐responders completing the treatment protocol were 98.4% (61/62) and 100% (5/5), respectively. The overall safety profiles of telaprevir‐based regimens were similar for Japanese patients with genotype 1 and 2 HCV infection who experienced treatment failure. Conclusion Telaprevir, in combination with PEG IFN / RBV , provided a high SVR rate for genotype 2 HCV , difficult‐to‐treat patients who had not achieved SVR during prior IFN ‐based treatment. The eRVR had a strong influence on the cure rate of telaprevir‐based therapy. In addition, the continuation of telaprevir‐based treatment for up to 24 weeks was a significant predictor of SVR .
Type of Medium:
Online Resource
ISSN:
1386-6346
,
1872-034X
Language:
English
Publisher:
Wiley
Publication Date:
2015
detail.hit.zdb_id:
2006439-1
Permalink